19-396 - Left Heart Chamber Disorder(Atrial) and Blood Clotting Medications used in Prevention After a Stroke of Unknown OriginStatus: open
AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at firstname.lastname@example.org.
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
Providers Associated With This Trial
- Rebecca Sugg, M.D., F.A.H.A.NeurologistAssociate Professor of Neurology